Institutional equity research analysts tracking Atea Pharmaceuticals (NASDAQ: AVIR) maintain consensus price targets projecting potential upside from its current baseline, with individual long-term model forecasts predicting valuation ranges between $5.00 and $10.00 USD dependent upon upcoming clinical trial milestones and pipeline readouts.